Differential (Click to cross reference) adverse drug reaction atypical autoimmune disease cancer associated myopathy carcinoma cardiotoxicity cauda equina cauda equina, enhancement cauda equina, lesion of chemotherapy, CNS treatment and complications with complications cranial nerve palsies creatine phosphokinase(CPK)elevated diabetes insipidus dropped head syndrome drug induced neurologic disorders duvalumab efficacy electromyogram encephalitis encephalitis, autoimmune facial nerve palsy fever gammaglobulin therapy, intravenous granulomatous hypophysitis Guillain Barre syndrome headache iatrogenic neurologic disorders immune checkpoint inhibitors immune-related adverse events immunomodulation immunosuppression immunosuppressive agents immunotherapy ipilimumab limb-girdle weakness melanoma, malignant meningismus meningitis meningitis, drug induced misdiagnosis monoclonal antibodies MRI, abnormal muscle biopsy muscle pain muscle weakness muscle weakness, proximal myasthenia gravis myasthenia gravis, drug induced myocarditis myopathy myopathy, inflammatory myopathy, necrotizing myopathy, necrotizing, immune-mediated myositis neoplasm, metastatic to CNS neoplasm, metastatic to CNS-treatment of neurologic complications of, systemic cancer neurologic disease neurologic disease, diagnoses of neuromuscular junction neuromuscular junction, abnormality of neuropathy neuropathy, iatrogenic neuropathy, medication induced neuropathy, sensory neurotoxic nivolumab ocular motility, disorders of paresthesias pembrolizumab pituitary stalk pituitary stalk, enlarged plasmapheresis polyneuropathy, chronic inflammatory demyelinating prognosis ptosis respiratory failure review article safety steroid steroid therapy, CNS treatment and complications with treatment of neurologic disorder weakness workup

Showing articles 0 to 6 of 6 Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies Neurol 92:663-674, Johansen, A.,et al, 2019 Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab J Immunother Cancer 6:11, Cafuir, L.,et al, 2018 Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain NEJM 379:722-730,789, Tawbi, H.A.,et al, 2018 Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer Neurol 91:e985-e994, Touat, M.,et al, 2018 Neurological Immune-Related Adverse Events of Ipilimumab Pract Neurol 13:278-280, Bot, I.,et al, 2013 Showing articles 0 to 6 of 6